Navigation Links
Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012
Date:3/13/2013

a collaboration partner to help fund clinical development and, if approved, commercialization.

Conference Call Today at 5 p.m. Eastern Time (2:00 p.m. Pacific Time)
The Orexigen management team will host a teleconference and webcast to discuss the fourth quarter and full year 2012 financial results and recent business highlights. The live call may be accessed by phone by calling (888) 895-5479 (domestic) or (847) 619-6250 (international), participant code 34404715. The webcast can be accessed live on the Investor Relations section of the Orexigen web site at http://www.orexigen.com, and will be archived for 14 days following the call.

About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave, which has completed Phase 3 clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com.

Forward-Looking Statements
Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "should," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are based on the Company's current beliefs and expectations. These forward-looking statements include statements regarding the timing of the interim analysis and resubmission of the  Contrave NDA, the  ra
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
2. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
4. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
5. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
6. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
7. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
8. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
9. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
10. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
11. Orexigen Therapeutics to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , September 2, 2014 , ... patients, quality of life and treatment satisfaction [ ... ]        ... 2014, 02 September 2014, Barcelona, Spain ... the PREvention oF thromboembolic events-European Registry in Atrial Fibrillation ...
(Date:9/2/2014)... ,S-HERTOGENBOSCH, the Netherlands , Sept. 2, ... expanded its North American operations through its subsidiary HealthLink ... fulfillment and order to cash services for medical device ... our global ERP platform. Building on the ... in Europe with customer service, ...
(Date:9/2/2014)... , Sept. 2, 2014 /PRNewswire-iReach/ -- The ... by universal healthcare coverage and good access to ... population and its associated disease burden, well-defined regulatory ... introduction of a new manufacturing policy will drive ... However, a focus on generic substitution and price ...
Breaking Medicine Technology:One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 2One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 3One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 4One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 5One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 6One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 7One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines 8HealthLink Europe opens North American medical warehouse operation 2Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 2Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 3Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 4Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 5
(Date:9/2/2014)... ROCHESTER, Minn. How well patients recover from ... their medical conditions and the operations themselves. Family ... risk of surgical complications, a Mayo Clinic study ... operation may reduce patients, stress, speed their recoveries ... The study specifically looked at colon cancer patients, ...
(Date:9/2/2014)... Vancouver, BC (PRWEB) September 02, 2014 ... Research ( http://www.idataresearch.com ), the leading global authority ... urological device market is expected to grow ... be fueled by an increase in the number ... urinary and kidney stones. This market includes TURP ...
(Date:9/2/2014)... On Saturday, September 6, 2014, The Concilio will present its ... Get Up! Get Moving!®. This event promotes Hispanic family physical ... people of all ages and all sizes. The event, which ... at Kiest Park Recreation Center, 3080 S. Hampton Road, in ... 2007, we have partnered with National Alliance for Hispanic Health ...
(Date:9/2/2014)... The American Healthcare Documentation Professionals Group (AHDPG) today ... ICD-10 Medical Coding Bridge Program. The purpose of this ... to students who are seeking to launch an exciting ... the uncertainty brought on by the federal government’s decision ... 2015. , AHDPG’s Free-Tuition Guarantee is simple and available ...
(Date:9/2/2014)... HealthDay Reporter , MONDAY, Sept. 1, 2014 (HealthDay ... boost their heart health, cutting down on carbohydrates may work ... In a small clinical trial of obese adults, researchers found ... weight over a year than those who followed a low-fat ... and triglyceride levels, the research team reports in the Sept. ...
Breaking Medicine News(10 mins):Health News:Family conflicts, other non-physical worries before cancer surgery raise patients' complication risk 2Health News:European Urological Device Market Is Expected to Grow to over €2 billion by 2020: Led by Coloplast, Wellspect HealthCare, Teleflex, C. R. Bard and Olympus 2Health News:European Urological Device Market Is Expected to Grow to over €2 billion by 2020: Led by Coloplast, Wellspect HealthCare, Teleflex, C. R. Bard and Olympus 3Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4Health News:American Healthcare Documentation Professionals Group (AHDPG) Launches Free-Tuition Guarantee for Its ICD-10 Medical Coding Bridge Program 2Health News:American Healthcare Documentation Professionals Group (AHDPG) Launches Free-Tuition Guarantee for Its ICD-10 Medical Coding Bridge Program 3Health News:Low-Carb Beats Low-Fat for Weight Loss, Heart Health: Study 2Health News:Low-Carb Beats Low-Fat for Weight Loss, Heart Health: Study 3
... suffered a set back following the testing by the ... heavy metals in the exported traditional medicinal preparations. // ... by the Health Canada, a part of the Canadian ... highlighted the high concentrations of heavy metals such as ...
... well known. These contain the omega-3 fatty acids EPA and ... has been found that DHA plays an important role in ... women should consume it. ,The alternative to fish-oil supplements ... In this case, the concern is contamination with mercury, which ...
... was associated with several alleged miscarriages of justice has ... ,This decision has been hailed as one to preserve ... health officials in Saskatchewan have voted to curtail practicing ... Charles Smith. ,Smith had been granted ...
... the population is under threat from a drinking problem. This ... Victoria's Centre// for Addictions Research of B.C. compared drinking patterns ... were based on the Canadian Addiction Survey done in 2004. ... exceeded the guidelines for alcohol consumption and 53 per cent ...
... convicted of spreading the dreaded HIV virus since he had ... ,"The message this sends I think is when ... that fact to any perspective partners that you have," commented ... came to testify against Nduwayo were very courageous since they ...
... Disease (GICD) have identified a growth factor in heart development ... diseases. ,the study, published in the online edition ... on the role of short RNAs in the early stages ... called as miRNAs, could play a key role in the ...
Cached Medicine News:Health News:Export Of Ayurvedic Medicines Affected Due To High Heavy Metal Content 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: